CD19 and melanoma: By implementing SeneVick retrospectively in a scRNA dataset from 48 melanomas treated exclusively with immune checkpoint inhibitors (PD1, CTLA4 or combined inhibition), we observed a considerable signature enrichment in the immune cell populations of NRs, comprising CD4+ and CD8+ T-cells, NK and B-cells (CD19+/CD20+), that was independent of patient’s age and other clinical features (Fig. 3).